U.S. Pharmaceuticals & Biotech Strong Balance Sheet Stocks

Niagen Bioscience

Market Cap: US$462.1m

Operates as a bioscience company engages in developing healthy aging products.

Barinthus Biotherapeutics

Market Cap: US$28.4m

A clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer.

Stevanato Group

Market Cap: US$6.0b

Engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific.

RenovoRx

Market Cap: US$28.2m

A clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment.

Septerna

Market Cap: US$254.2m

A clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products candidates for the treatment of endocrinology, immunology and inflammation, and metabolic diseases.

PharmaCyte Biotech

Market Cap: US$8.5m

A biotechnology company, develops and commercializes cellular therapies for cancer in the United States.

LENZ Therapeutics

Market Cap: US$558.0m

Operates as a biopharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States.

Kyverna Therapeutics

Market Cap: US$89.0m

Kyverna Therapeutics, Inc., clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases.

BioNTech

Market Cap: US$23.2b

A biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany.

Pacira BioSciences

Market Cap: US$1.1b

Engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States.

Nutriband

Market Cap: US$52.4m

Develops a portfolio of transdermal pharmaceutical products.

Passage Bio

Market Cap: US$22.5m

A genetic medicines company, develops gene therapies for central nervous system diseases.

Astria Therapeutics

Market Cap: US$228.0m

A biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States.

Qiagen

Market Cap: US$9.1b

Provides sample to insight solutions that transform biological samples into molecular insights in the Netherlands and internationally.

ProKidney

Market Cap: US$94.7m

A clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States.

Aptevo Therapeutics

Market Cap: US$3.3m

A clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States.

Amylyx Pharmaceuticals

Market Cap: US$323.4m

A clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States.

Context Therapeutics

Market Cap: US$70.0m

A biopharmaceutical company, develops products for the treatment of solid tumors.

Dianthus Therapeutics

Market Cap: US$565.7m

A clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases.

Anbio Biotechnology

Market Cap: US$276.1m

Provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally.

ACADIA Pharmaceuticals

Market Cap: US$2.4b

A biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States.

Biogen

Market Cap: US$16.9b

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally.

Exelixis

Market Cap: US$9.9b

An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.

Protara Therapeutics

Market Cap: US$143.8m

A clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases.

Trevi Therapeutics

Market Cap: US$537.6m

A clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough conditions targeting the central and peripheral nervous systems.

Dermata Therapeutics

Market Cap: US$4.4m

A late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications.

Mural Oncology

Market Cap: US$17.7m

Operates as a clinical-stage oncology company that focuses on discovering and developing immunotherapies for the treatment of patients with cancer.

MacroGenics

Market Cap: US$81.4m

A clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States.

Ventyx Biosciences

Market Cap: US$68.9m

A clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases.

GH Research

Market Cap: US$558.3m

Together with its subsidiary, a clinical-stage biopharmaceutical company, engages in developing treatments for depression in the United States.

Lantern Pharma

Market Cap: US$34.6m

A clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process.

Boundless Bio

Market Cap: US$27.2m

A clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by interrogating extrachromosomal DNA.

Sagimet Biosciences

Market Cap: US$74.4m

A clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States.

180 Life Sciences

Market Cap: US$4.4m

A clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases.

4D Molecular Therapeutics

Market Cap: US$121.8m

A late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States.

Exicure

Market Cap: US$73.2m

Does not have significant operations.